Abu Dhabi Smart Solutions and Services Authority, in collaboration with the Abu Dhabi Health Services Company (SEHA), organized a seasonal influenza vaccination campaign for its employees as a preventive measure to contain the spread of influenza virus at this time of the year.
Abu Dhabi, 22 November 2018
Abu Dhabi Smart Solutions and Services Authority, in collaboration with the Abu Dhabi Health Services Company (SEHA), organized a seasonal influenza vaccination campaign for its employees as a preventive measure to contain the spread of influenza virus at this time of the year.
The campaign aims to increase awareness among all members of the community, about the need for timely vaccination, provision of adequate vaccines for the target groups, vaccinating the maximum number of people and reducing the health, economic and social burden of influenza.
Influenza is a seasonal illness and its severity varies according to the immunity level of the affected person. However, pregnant women, children, the elderly and people with chronic diseases are more susceptible to complications, and the aim of the vaccination campaign is to reduce its occurrence in these vulnerable groups.
Mohammed Al Shehhi, Executive Director of Support Services at Smart Solutions and Services Authority said: “The campaign coincided with the start of the influenza season, so that the necessary preventive action could be taken in response to the objectives of the Ministry of Health and Prevention (MOHAP) to provide comprehensive and integrated healthcare in innovative and sustainable ways, ensuring the community’s protection against the illness.”
Al-Shehhi added that the Authority continues to make concerted efforts to increase the health awareness levels of its employees and place top priority on their safety. He pointed out that the Authority is particularly keen to organize such preventive campaigns, as they have a key role in safeguarding the health of the public and preventing the spread of infectious diseases such as influenza.
The vaccine is administered at the beginning of winter every year to the most susceptible population groups, such as children under 5 years, pregnant women, diabetics, asthma patients, heart patients and those with liver complications.
